Carriers

Carrier-mediated transport

• Carriers are integral membrane proteins that facilitate the movement of specific substrates across lipid bilayers.

• Unlike ion channels, carriers undergo conformational changes to alternately expose binding sites to either side of the membrane (alternating access).

• Transport can be passive (facilitated diffusion) or secondary active (coupled to ion gradients).

• Carriers have been classically modeled using valinomycin, a small peptide ionophore

Valinomycin structure

• Valinomycin is a cyclic dodecadepsipeptide with a trimeric repeat of:

  • L-lactate

  • L-valine

  • D-hydroxyvaleric acid

  • D-valine

• Forms a ring structure:

  • Hydrophilic inner pocket: binds K⁺ via carbonyl oxygens.

  • Lipophilic outer surface: allows diffusion through membranes.

• Selectivity: Highly selective for K⁺ over Na⁺ because the free energy of dehydration is lower for K⁺

Valinomycin mechanism

1. Ion binding: Empty valinomycin binds K⁺ on the side of higher concentration.

2. Diffusion across membrane: Lipophilic valinomycin-K⁺ complex diffuses through the lipid bilayer.

3. Release of substrate: K⁺ released where concentration is lower.

4. Carrier re-orientation: Empty valinomycin returns to original side.

Key point: Net transport depends on the electrochemical gradient of K⁺

Valinomycin kinetics

• Carrier-mediated transport can be described using Michaelis-Menten kinetics:

  • Vmax: Maximum transport rate; reflects carrier re-orientation steps.

  • Km: Substrate concentration at half-maximal transport; reflects binding/release affinity.

• Plant root example: Two kinetically distinct K⁺ uptake mechanisms:

  1. High-affinity, low-capacity (micromolar K⁺)

  2. Low-affinity, high-capacity (millimolar K⁺)

Limitation: Valinomycin provides kinetic insights but is not a mechanistic model for protein carriers, which are large and undergo conformational changes

Protein Carriers: Alternating Access Model

• Substrate-binding site alternately exposed to extracellular and intracellular sides.

• Steps for a typical uniporter (e.g., GLUT1):

  1. Substrate binds to outward-facing binding site.

  2. Conformational change reorients binding site inward.

  3. Substrate released into low-concentration cytosol.

  4. Empty carrier reverts to outward-facing state.

Kinetic implication:

• Steps 1 & 3 → substrate affinity (Km)

• Steps 2 & 4 → rate of conformational change (Vmax)

GLUT1 (Human Glucose Transporter) physiological role

• Facilitated (Passive) diffusion of glucose into erythrocytes and endothelial cells.

• Basal glucose uptake (~5 mM blood glucose).

• Mutations → GLUT1 deficiency syndrome (epilepsy, developmental delay).

• Overexpression → marker for cancer metabolism (Warburg effect)

GLUT1 (Human Glucose Transporter) structural features

• Member of the sugar porter subfamily, part of the major facilitator superfamily (MFS).

• 12 transmembrane segments (TMs), divided into N- and C-terminal domains (each with 6 TMs, 3+3 inverted repeats).

• Intracellular helical bundle (ICH): 4 short helices connecting N and C domains. Unique to sugar porter subfamily; acts as a latch for conformational changes.

• Crystal structure captured in inward-open conformation

GLUT1 (Human Glucose Transporter) transport mechanism (alternating access)

• Outward-open preferred state (substrate-free).

• Substrate binding at C-domain → induces contact with N-domain.

• Conformational rearrangement → extracellular gate closes, inward-open conformation formed.

• Substrate dissociation into low-glucose cytosol.

• Carrier returns to outward-open conformation

Disease-related mutations of GLUT1

• Cluster I: Substrate-binding residues → reduce glucose affinity.

• Cluster II: ICH interactions → stabilize intracellular gate; mutations impede alternating access.

• Cluster III: Extracellular gate → mutations affect gating and conformational switching

GLUT1 Comparison with Bacterial Homologues

• XylE and GlcP are proton-coupled symporters (active transport).

• GLUT1 is a uniporter (facilitated diffusion, no proton coupling).

• Shared mechanism: alternating access, but energy coupling differs

Neurotransmitter Sodium Symporters (NSS)

• Secondary active transporters at synapses.

• Example: Dopamine transporter

  • Clears neurotransmitters from synaptic cleft.

  • Uses Na⁺ (and Cl⁻) electrochemical gradient.

  • Medical relevance: target of antidepressants, cocaine, amphetamines

Neurotransmitter Sodium Symporters (NSS) Structure & Mechanism

• Multiple transmembrane domains with hairpin loops forming gates.

• Alternating access model:

  • Extracellular Na⁺ increases neurotransmitter affinity.

  • Low intracellular Na⁺ → substrate release

GLUT2

• facilitator

• liver, pancreas

• passive diffusion

• Glucose sensor, absorption

SGLT1

• Secondary Active carrier

• Gut epithelium

• Na+ coupled

• Glucose uptake into cytosol

Na⁺/Ca²⁺

• antiporter

• cardiac muscle

• Na⁺ gradient-driven

• Calcium extrusion post-contraction

Na⁺/H⁺ (plant vacuole)

• antiporter

• plant vacuole

• H⁺ gradient-driven

• Salt tolerance, nutrient accumulation

Root minerals

• Proton symporters

• plant roots

• H⁺-coupled

• Uptake of K⁺, Mg²⁺, phosphate, nitrogen

Kinetic Modeling of Carriers

• Carrier transport often exhibits Michaelis-Menten kinetics:

  • Vmax → maximal transport rate, limited by conformational changes.

  • Km → substrate affinity, determined by binding/release steps.

• Useful for predicting physiological activity and designing experiments/drugs

Integrating Structure and Function

• Valinomycin: kinetic model, diffusion-based.

• GLUT1/NSS: protein-based, conformational change-driven.

• Structural insights allow:

  • Mapping disease mutations

  • Understanding gating and binding mechanisms

  • Rational drug design targeting transporters